Characteristic

Low expression of TM4SF19

High expression of TM4SF19

p

n

207

207

T stage, n (%)

0.003

T1

3 (0.8%)

2 (0.5%)

T2

75 (19.7%)

44 (11.6%)

T3

83 (21.8%)

113 (29.7%)

T4

28 (7.4%)

32 (8.4%)

N stage, n (%)

0.103

N0

124 (33.5%)

115 (31.1%)

N1

19 (5.1%)

27 (7.3%)

N2

38 (10.3%)

39 (10.5%)

N3

1 (0.3%)

7 (1.9%)

M stage, n (%)

0.209

M0

119 (55.9%)

83 (39%)

M1

4 (1.9%)

7 (3.3%)

Pathologic stage, n (%)

0.005

Stage I

3 (0.7%)

1 (0.2%)

Stage II

80 (19.4%)

50 (12.1%)

Stage III

61 (14.8%)

81 (19.7%)

Stage IV

61 (14.8%)

75 (18.2%)

Radiation therapy, n (%)

0.194

No

182 (46.9%)

185 (47.7%)

Yes

14 (3.6%)

7 (1.8%)

Primary therapy outcome, n (%)

<0.001

PD

21 (5.9%)

49 (13.7%)

SD

13 (3.6%)

18 (5%)

PR

11 (3.1%)

11 (3.1%)

CR

133 (37.3%)

101 (28.3%)

Gender, n (%)

0.264

Female

49 (11.8%)

60 (14.5%)

Male

158 (38.2%)

147 (35.5%)

Race, n (%)

<0.001

Asian

36 (9.1%)

8 (2%)

Black or African American

11 (2.8%)

12 (3%)

White

151 (38%)

179 (45.1%)

Age, n (%)

0.921

≤70

118 (28.5%)

116 (28%)

>70

89 (21.5%)

91 (22%)

Weight, n (%)

0.437

≤80

107 (28.8%)

98 (26.4%)

>80

79 (21.3%)

87 (23.5%)

Height, n (%)

0.351

≤170

85 (23.3%)

73 (20%)

>170

100 (27.4%)

107 (29.3%)

BMI, n (%)

0.128

≤25

85 (23.4%)

68 (18.7%)

>25

99 (27.2%)

112 (30.8%)

Histologic grade, n (%)

<0.001

High Grade

186 (45.3%)

204 (49.6%)

Low Grade

19 (4.6%)

2 (0.5%)

Subtype, n (%)

<0.001

Non-Papillary

115 (28.1%)

160 (39.1%)

Papillary

90 (22%)

44 (10.8%)

Lymphovascular invasion, n (%)

0.680

No

67 (23.7%)

63 (22.3%)

Yes

74 (26.1%)

79 (27.9%)

Smoker, n (%)

0.632

No

57 (14.2%)

52 (13%)

Yes

143 (35.7%)

149 (37.2%)

OS event, n (%)

<0.001

Alive

133 (32.1%)

98 (23.7%)

Dead

74 (17.9%)

109 (26.3%)

DSS event, n (%)

0.002

Alive

152 (38%)

122 (30.5%)

Dead

48 (12%)

78 (19.5%)

PFI event, n (%)

0.007

Alive

131 (31.6%)

103 (24.9%)

Dead

76 (18.4%)

104 (25.1%)

Age, median (IQR)

68 (59, 75)

69 (61.5, 76)

0.223